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Background: Because Plasmodium falciparum displays increase tolerance against the recommended artemisinin
combination therapies (ACT), new classes of anti-malarial drugs are urgently required. Previously synthesized
artemisinin-aminoquinoline hybrids were evaluated to ascertain whether the potent low nanomolar in vitro
anti-plasmodial activity would carry over in vivo against Plasmodium vinckei. A snapshot pharmacokinetic analysis was carried
out on one of the hybrids to obtain an indication of the pharmacokinetic properties of this class of anti-malarial drugs.
Methods: In vitro activity of hybrids 2 and 3 were determined against the 3D7 strain of P. falciparum. Plasmodium
vinckei-infected mice were treated with hybrids 1 – 3 for four days at a dosage of 0.8 mg/kg, 2.5 mg/kg, 7.5 mg/kg or
15 mg/kg intraperitoneally (ip), or orally (per os) with 2.7 mg/kg, 8.3 mg/kg, 25 mg/kg or 50 mg/kg. Artesunate was used
as reference drug. A snapshot oral and IV pharmacokinetic study was performed on hybrid 2.
Results: Hybrids 1 – 3 displayed potent in vivo anti-malarial activity with ED50 of 1.1, 1.4 and <0.8 mg/kg by the ip route
and 12, 16 and 13 mg/kg per os, respectively. Long-term monitoring of parasitaemia showed a complete cure of mice
(without recrudescence) at 15 mg/kg via ip route and at 50 mg/kg by oral route for hybrid 1 and 2, whereas artesunate
was only able to provide a complete cure at 30 mg/kg ip and 80 mg/kg per os.
Conclusions: These compounds provide a new class of desperately needed anti-malarial drug. Despite a short half-life
and moderate oral bioavailability, this class of compounds was able to cure malaria in mice at very low dosages. The
optimum linker length for anti-malarial activity was found to be a diaminoalkyl chain consisting of two carbon atoms
either methylated or unmethylated.
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Partial artemisinin resistance has emerged in western
Cambodia and has the potential to spread to different
parts of the region, subsequently becoming a global
threat for malaria control and treatment. There are cur-
rently no alternative drugs to artemisinin derivatives [1-3].
A major drawback of the artemisinin derivatives is their
short half-lives and susceptibility to recrudescence, when
given as monotherapy [4]. CYP-mediated autoinduction* Correspondence: david.nda@nwu.ac.za
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reproduction in any medium, provided the orof artemisinin metabolism has been reported to be the
underlying mechanism recrudescence [5,6].
Hybrid molecules, as described by Meunier [7], are
composed of two distinct moieties joined covalently,
which will act as two distinct pharmacophores. The risk
of treatment failure is reduced and the partner drug may
be protected from the spread of resistance. The concept
of the formation of a hybrid, especially in the treatment
of malaria, has already been adopted by a number of
groups [7-12].
Walsh et al. synthesized a novel artemisinin-quinine
hybrid by coupling dihydroartemisinin directly to the
carboxylic acid derivative of quinine via an ester-linkage
[13]. The hybrid had potent in vitro activity againstal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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arum that was superior to that of quinine alone, artemi-
sinin alone and to a 1:1 mixture of the two, suggesting a
tangible benefit in terms of activity from linking the two
molecules covalently [14].
The hybrids of the present study have been previously
synthesized [15]. DHA (dihydroartemisinin) was treated
with bromoethanol in the presence of boron trifluoride
etherate to give 2-(10β-dihydroartemisinoxy) ethylbromide,
which upon treatment with different aminoquinolines
provided the new hybrids. All compounds were obtained as
the 10-β-isomers [16] and displayed good selectivity to-
wards P. falciparum in vitro (SI ≥ 20). Based on IC50, resist-
ance index (RI) and selectivity index (SI) values, those
hybrids with the best anti-plasmodial activity were selected
for further investigation. Hybrids 1 – 3 (Figure 1) were
prepared as the oxalates for stability and solubility reasons.
The aim of this study was to elucidate whether the po-
tent in vitro anti-plasmodial activity of the selected three
hybrids would be carried over in vivo against Plasmodium
vinckei and to determine the pharmacokinetic properties
of this class of anti-malarial drugs by performing a snap-
shot pharmacokinetic analysis on hybrid 2.Methods
In vitro anti-malarial activity against 3D7 strain
The 3D7 strain of P. falciparum was asexually cultured
in human blood in complete medium (RPMI 1640
supplemented with 25 mM Hepes, pH 7.4) and 10% AB+
human serum [17]. Drug effects were measured in
microtitre plates on suspensions of asynchronous P. fal-
ciparum infected red blood cells (1.5% final haematocrit,
0.6% parasitaemia) according to Desjardins et al. [18].
Drugs, previously dissolved in DMSO, were diluted in cul-
ture medium so that the final DMSO concentration never
exceeded 0.25%. After 48 h incubation at 37°C parasite
growth was assayed by the incorporation of [3H]-hypoxan-















Figure 1 The structures of artemisinin-quinoline hybrids 1 – 3. The ch
1 – 3 only differs with one methylene group in the linker and its position in t
amino]ethyl, 2-[(2-aminopropyl)amino]ethyl and 2-[(3-aminopropyl)amino]eth18 h. Analyses of dose-effect curves were performed with
the Graphpad Prism analytical software. The results are
expressed as IC50, corresponding to the drug concentra-
tion leading to 50% parasite growth inhibition. Values are
the means of at least two independent experiments (differ-
ent cell cultures, different drug dilution stocks), each
performed in duplicates.
In vivo anti-malarial activity against P. vinckei
In each experiment, female Swiss OF1 mice (Charles
River Laboratories, France) were infected on day 0 (D0)
by intravenous injection into the caudal vein of 107 P.
vinckei-infected erythrocytes (BY strain) in 200 μl 0.9%
NaCl. These injections lead to a parasitaemia on day 1
(D1) of between 0.3% and 1.5%. Mice were treated once
a day for four days on D1, D2, D3 and D4 intraper-
itoneally (ip) with 0.8 mg/kg, 2.5 mg/kg, 7.5 mg/kg or
15 mg/kg of the compound, or orally (per os) with
2.7 mg/kg, 8.3 mg/kg, 25 mg/kg or 50 mg/kg. Hybrids
1–3 were dissolved in DMSO and were administered in
volumes of 100 μL. Each group consists of 3 mice and
the control group received only the vehicle (DMSO). On
D5, the ED50 (effective dose) was determined using
Giemsa-stained thin blood smears and flow cytometry
(Yoyo 1 iodide (491/509) – Invitrogen) [19]. The survival
of the mice was monitored for up to one month after
the end of the treatment.
Snapshot pharmacokinetics
The pharmacokinetic properties of hybrid 2 were
evaluated in a mouse model. This study was approved
by the Ethics Committee of the University of Cape
Town, approval number 009/034.
Mouse strain, formulation and mice study protocol
The animals used were male C57/BL6 mice, weighing
approximately 25 g each. The concentration of the test
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experiments. Hybrid 2 was dissolved in DMSO, and
water was added (1:9, v/v). The test compounds were
administered orally and intravenously. Test animals were
randomly divided into 2 groups. Each group consisted of
three mice. Group A received hybrid 2 at an oral gavage
dose concentration of 20 mg/kg. Group B received
hybrid 2 IV at a concentration of 2 mg/kg. The animals
were anesthetized for the IV via dorsal penile vein bolus
injections. Blood samples (40 μL) were collected before,
and at 10, 20, 30, 40 and 50 min after oral gavage dosing
(Group A), and at 5, 15, 25, 35 and 50 min after IV dos-
ing (Group B). The blood samples were collected on ice
into 0.8 mL lithium heparin gel tubes. The samples were
centrifuged at 1500 G for 10 min, and the plasma layer
was transferred to 1.5 mL micro centrifuge tubes and
stored at – 80°C until analysis.Pharmacokinetic sample analysis
An LC/MS/MS system (Shimadzu HPLC and an AB
Sciex API 3200 Q-Trap mass spectrometer) was used to
analyse the plasma samples. A sensitive and selective
assay was developed to determine the plasma concen-
trations of hybrid 2.Table 1 In vitro IC50 of hybrids 1–3 against 3D7, D10 and
Dd2 P. falciparum strains
Compound IC50 (nM) ± SD
3D7 D10 Dd2
1 ND 14.9 ± 0.1 20.8 ± 3.6
2 20.5 ± 1.2 21.5 ± 0.1 25.7 ± 1.1
3 5.2 ± 0.7 14.3 ± 2.7 19.8 ± 0.3
DHA ND 5.1 ± 0.6 2.1 ± 0.3
CQ 20 ± 1.6 21.5 ± 6.7 157.9 ± 52.7
ND = not determined.LC/MS/MS summary
Twenty microliters of plasma was precipitated with a
100 μl acetonitrile. The samples were vortexed for one
minute, sonicated for 5 min and centrifuged at 13,000 G
for 5 min. The supernatant was transferred to a 96 well
plate, and 10 μL was injected onto the HPLC column.
Gradient chromatography was performed using a
Phenomenex, Gemini-NX (5μL, C18, 110A, 50 x 2 mm)
analytical column using a Shimadzu HPLC. Mobile
phase A consisted of acetonitrile and mobile phase B
consisted of a mixture of 4 mM ammonium acetate and
0.1% formic acid (1:1, v/v). The organic solvent was
increased from 5% to 95% over 4 min, with an equilibra-
tion time of 3 min between 4 and 7 min. The flow-rate
was set at 0.5 mL/min and 10 μL was injected onto the
analytical column. The samples were cooled to 5°C
whilst awaiting injection.
Detection of hybrid 2 was performed using an AB
Sciex API 3200 Q-Trap mass spectrometer (ESI in the
positive ion mode, MRM). The mass spectrometer was
operated at unit resolution in the multiple reaction
monitoring (MRM) mode, monitoring the transition of
the protonated molecular ions at m/z 532.3 to the prod-
uct ions at m/z 205.2. Calibration standards (8 levels)
were prepared in mouse plasma, at concentrations ran-
ging from 7.8 to 1000 ng/mL. The calibration standards
were analysed in duplicate with the study samples.Pharmacokinetic parameters and statistical evaluation
Non-compartmental analysis was used to calculate the
pharmacokinetic parameters for hybrid 2 (Summit
pharmacokinetic software, version 2.0). The following
pharmacokinetic parameters were calculated: Maximum
plasma concentration (Cmax [ng/mL]) and corresponding
time (Tmax [min]), Apparent terminal half-life (t½ [min]),
Total plasma exposure (AUC0-Inf [ng.min/mL]), Volume
of distribution [L/kg], Plasma clearance (CL [L/min/kg])
and percentage oral bioavailability (%BA).Results
In vitro anti-malarial activity
The in vitro anti-plasmodial activity was determined for
hybrid 2 and 3 against the 3D7 strain of P. falciparum.
The activity of all three compounds was previously
determined against the D10 and Dd2 strain. All results
are displayed in Table 1, including reference drugs; DHA
and chloroquine (CQ). The activity against the 3D7
strain resulted in similar values, when compared to the
anti-plasmodial activity previously determined for these
hybrids. Hybrid 3 displayed a very potent anti-plasmodial
activity against the 3D7 strain, with an IC50 value of 5.15 ±
nM, whereas the activity of hybrid 2 was similar to that of
CQ (20.5 ± and 20.0 ± 1.6 nM, respectively). Although all
three hybrids displayed very similar IC50 values against all
three strains, hybrid 3 had the best activity against all three
strains and was, therefore, classified as the best compound
based on the in vitro anti-plasmodial activity.In vivo anti-malarial activity of hybrids 1–3 after four
injections by the intraperitoneal route (ip)
At 7.5 mg/kg ip hybrid 1 displayed a strong anti-malarial
effect. Parasitaemia decreased from 0.67% to 0.27% be-
tween day 1 and 2. No parasitaemia was observed from
day 3 up to day 11. However, at this dose recrudescence
was observed for at least one mouse. A very potent anti-
malarial effect was exerted by artemisinin-quinoline hy-
brid 1 at 15 mg/kg, inducing a rapid and total clearance
of the parasites. On day 2, just before the second injec-
tion, parasitaemia decreased from 1% to 0.1%. All the
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observed from day 3 until after 30 days.
Hybrid 2 displayed a strong anti-malarial effect at
7.5 mg/kg (P = 0.03% vs. 86% for the control group).
However, recrudescence was observed which led to mice
death between day 14 and 17. At 15 mg/kg ip potent
in vivo anti-malarial activity was observed for hybrid 2. On
day 5, parasitaemia was 0% of the control (P = 0% vs. 86%
for the control group). At this dose, long term monitoring
showed no recrudescence, with no visualized parasitaemia
on day 17 and 100% of survival beyond day 20.
At 2.5 and 7.5 mg/kg, hybrid 3 decreased parasita-
emia to 0.02% of the control on day 5 for both two doses
(P = 0.02% vs. 86% for the control group). Recrudescence
occurred, which led to mice death between day 14 and 18.
A strong anti-malarial effect was observed in vivo against
P. vinckei at 15 mg/kg with hybrid 3 resulting in parasit-
aemia of 0.01% of the control on day 5. No recrudescence
was observed for two of the three mice. However, the
third mouse died on day 8, indicating 66% of survival be-
yond day 20.
In vivo anti-malarial activity of hybrids 1–3 after four
dosages by the oral route
At 25 and 50 mg/kg per os, hybrid 1 displayed very rapid
and potent in vivo anti-malarial activity against P.
vinckei. Parasitaemia decreased from 0.6% (day 1) to
0.01% and 0% for 25 and 50 mg/kg (day 2), respectively,
and was 0% on day 5. However, recrudescence was
observed at 25 mg/kg for two mice, leading to 66% of
mortality on day 17. No recrudescence was observed at
50 mg/kg per os for hybrid 1. All mice were alive on day 30.
A strong anti-malarial effect was observed with hybrid
2 at 25 mg/kg with parasitaemia of 8% of the control on
day 5. Rapid recrudescence of parasitaemia was shown
by mice death between day 8 and 15. At 50 mg/kg hy-
brid 2 displayed a potent in vivo anti-malarial activity,
with parasitaemia 0% of the control on day 5 (P = 0% vs.
93% for the control group). Long term monitoring
showed no recrudescence, with no parasite visualized on
day 17 thin blood smears and 100% survival beyond day
20, indicating a total clearance of parasitaemia.
Hybrid 3 exerted a strong anti-malarial effect at
25 mg/kg (P = 0.02% vs. 93% for the control group).
Delayed recrudescence led to mice death on day 15.
Very potent in vivo anti-malarial activity was displayed
at 50 mg/kg. The treatment decreased parasitaemia on
day 5 to 0.01% of the control (P = 0.01% vs. 93% for the
control group). At this dose, 2 of the 3 mice showed no
recrudescence, with no visualized parasitaemia on day
17. The third mouse showed 51% of parasitaemia on day
17 and died on day 18. At 50 mg/kg survival beyond day
17 is 66%.In vivo ED50 of artemisinin-quinoline hybrids
After P. vinckei infected mice were treated with hybrids
1 – 3 ip and per os parasitaemia, determined on day 5,
were expressed as a percentage of the control and
displayed as the ED50 on the graphs for each compound,
respectively. Oral absorption was calculated by the
ED50ip/ ED50per os ratio. The ip/per os ratio provides an
estimation of oral bioavailability for each compound.
Hybrid 1 presented good ED50 values of 1.1 mg/kg ip
and 12 mg/kg per os (Figure 2A), with an ip/per os ratio
of 9% in DMSO. ED50 values for hybrid 2 were 1.4 mg/
kg for ip route and 16 mg/kg for per os route (Figure 2B).
Oral absorption is evaluated by the ED50ip/ ED50per os
ratio which was 9.75% in DMSO. After a four day treat-
ment with hybrid 3, the ED50 ip was less than 0.8 mg/kg
and 13 mg/kg for the oral route (Figure 2C) with an
ED50ip/ ED50per os ratio < 6% in DMSO.
In comparison with these compounds, results obtained
for another well-known anti-malarial drug, artesunate
with the same four days experimental protocol were
provided. Plasmodium vinckei-infected mice were treated
via ip route at 1, 3, 10 and 30 mg/kg/day and per os route
at 1, 4, 20 and 80 mg/kg/day. Artesunate exerts a very sig-
nificant anti-malarial effect, with ED50 ip < 1 mg/kg and
ED50 per os = 1.8 mg/kg (Figure 2D).
At day 5 after ip treatment, artesunate reduced parasit-
aemia by 70% at 1 mg/kg. Higher doses were not able to
clear parasitaemia and 3% of the parasitaemia remained
after treatment with 30 mg/kg ip. None of the tested
doses allowed a complete cure and only 50% survival
was observed at 30 mg/kg ip. A similar profile was
observed after oral administration, with an ED50 of
1.8 mg/kg and a decrease of parasitaemia by 93% at
4 mg/kg.
Pharmacokinetics
A snapshot pharmacokinetic study was performed on
hybrid 2, which was selected as an example in order to
determine the pharmacokinetic properties of this class
of anti-malarial drugs. Three mice were used for each
experiment, each receiving 20 mg/kg orally or 2 mg/kg
intravenously (IV). The plasma concentration profiles of
the intact hybrid after oral and IV administration of hy-
brid 2 are displayed in Figure 3. The pharmacokinetic
parameters for the oral and IV data of hybrid 2 are
presented in Table 2.
A moderate pharmacokinetic profile was displayed by
hybrid 2. After a dose of 20 mg/kg per os, a maximum
oral concentration of 141 ± 56.8 ng/mL was reached
within 23.3 ± 5.77 min. The oral half-life was 3.91 ±
0.68 min, which was similar to the IV half-life (4.51 ±
1.22 min). The IV AUC was 32 times higher than the
oral AUC (3463 ± 895 ng.min/mL vs 112735 ±
125766 ng.min/mL), whereas the IV dose was 2 mg/kg.
































































































Figure 2 In vivo ED50 of hybrids 1 – 3 and artesunate. The in vivo ED50 of hybrid 1 (A), hybrid 2 (B), hybrid 3 (C) and artesunate (D) was
determined. Plasmodium vinckei-infected mice were treated once daily by ip (white squares) or po (black squares) injections for 4 consecutive
days. Parasitaemia was monitored at day 5 and expressed as a percentage of the control. Results are the mean of at least 3 mice per
dosage ± SD.
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the oral dosage and 0.44 ± 0.58 L/kg for the IV dosage.
Hybrid 2 presented a high oral clearance rate (6.1 ±
1.80 L/min/kg) and low oral bioavailability (0.31 ±
0.08%). A linear pharmacokinetic profile was displayed
by hybrid 2. For raw data of treatment with hybrid 1, see
Additional files 1 and 2
Discussion
All three hybrids displayed potent low nanomolar
in vitro anti-malarial activities, with IC50 values very
closely related, ranging from 5.15 – 25.7 nM, whereas
2.09 – 5.11 nM and 21.54 – 157.90 nM were the ranges
of DHA and CQ, respectively. The best in vitro activity
against the 3D7 strain was displayed by hybrid 3 (IC50 =
5.15 nM). It was clear from the data presented that this
class of compounds displayed a very potent and rapidA
Figure 3 Pharmacokinetic plasma concentration profiles for hybrids 1
graph A after oral administration of 20 mg/kg, whereas the 2 mg/kg IV datin vivo anti-malarial activity when optimum dosages were
applied, resulting in recrudescence if otherwise applied.
Hybrid 1 demonstrated a potent anti-malarial activity
via both intraperitoneal and oral routes. At 15 mg/kg ip
and 50 mg/kg per os rapid and total parasitaemia clear-
ance were induced. No visible sign of toxicity was
observed up to 50 mg/kg. No parasitaemia were observed
on the smears form day 3. Long term monitoring showed
100% survival on day 30 and no recrudescence was
observed. Artemisinin hybrid 1 provided a total cure of
malaria in vivo at these doses.
Hybrid 2 provided a complete clearance of parasit-
aemia and a total cure of malaria at 15 mg/kg by ip
route and at 50 mg/kg by oral route. Compared to hy-
brid 1, hybrid 2 displayed similar efficiency against P.
vinckei in vivo at the same doses allowing a total cure
and similar ED50 values (1.1 and 1.4 mg/kg ip for hybridB
and 2. Plasma concentration profiles for hybrid 2 are shown on
a are shown on graph B. Results are the mean of at least 3 mice ± SD.
Table 2 Pharmacokinetic parameters of hybrid 2 after




Mean ± SD (oral) Mean ± SD (IV)
Cmax [ng/ml] 141 ± 56.8 ND
Tmax [min] 23.3 ± 5.8 ND
Apparent Terminal t½ [min] 3.9 ± 0.7 4.5 ± 1.2
AUC0-Inf [ng.min/ml] 3463 ± 895 112735 ± 125766
VD/F [L/kg]
a 34 ± 10.8 0.4 ± 0.6
Plasma CL/F [L/min/kg]a 6.1 ± 1.8 0.06 ± 0.07
%BA 0.3 ± 0.1 ND
a For the oral experiment, apparent oral CL and VD were reported; ND = not
determined.
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per os for hybrid 1 and hybrid 2, respectively).
Although the four day treatment with hybrid 3
provided good anti-malarial efficacy against P. vinckei
in vivo at 2.5 mg/kg ip and 25 mg/kg per os (doses where
parasitaemia is less than 10% on day 5), survival rate was
66%. Therefore, a complete clearance of parasitaemia
and a total cure of malaria in vivo were not obtained by
hybrid 3.
Artesunate, the reference drug, displayed ED50 ip and
per os values of < 1 mg/kg and 1.8 mg/kg, respectively.
However, despite these low ED50 values, artesunate was
only able to completely cure mice at doses about 40
times higher. Clearance of parasitaemia was only
obtained at 30 mg/kg ip and 80 mg/kg per os, whereas
complete clearance was obtained at 15 mg/kg ip and
50 mg/kg per os for hybrid 1 and 2.
The pharmacokinetic profile (mean ± SD) of hybrid 2
was similar to that of DHA. Hybrid 2 reached a max-
imum concentration of 141 ± 56.8 ng/mL within 23 ±
5.77 min after a concentration of 20 mg/kg were
administrated orally, whereas DHA reached a maximum
concentration of 142.2 ± 21.1 ng/mL, in 48 ± 6 min after
a dose of 10 mg/kg [20]. However, according to the
recorded data DHA displayed a much longer half-life ip
than hybrid 2 (25 min vs 3.9 min) [21]. Subsequently
DHA also displayed a higher AUC than hybrid 2 (8748
± 2016 ng.min/mL vs 3463 ± 895 ng.min/mL) [20]. The
oral volume of distribution of DHA was higher than that
of hybrid 2 (353.5 ± 194.9 L/kg vs 34 ± 10.8 L/kg),
whereas the clearance rate for hybrid 2 was 5 times that
of DHA (6.1 L/min/kg vs 1.19 L/min/kg) [20]. Hybrid 2
resulted in a significantly lower oral bioavailability,
0.31%, compared to 19 – 35%, which has been reported
for artemisinin derivatives [22].
The high values for oral artemisinin clearance either
indicated moderate absorption or high first-pass extrac-
tion, which also explain the time dependency of DHA
[4] and hybrid 2. Moderate bioavailability displayed byhybrid 2 could be explained by rapid metabolism. How-
ever, metabolites – not identified by the LC/MS/MS
assay – are expected to be very active due to their potent
in vivo anti-malarial activity.
Conclusions
Hybrids 1 and 2 were able to completely cure mice at
15 mg/kg via the intraperitoneal route and at 50 mg/kg
for oral route, whereas artesunate is only able to provide
a complete cure at 30 mg/kg ip and 80 mg/kg per os.
The artemisinin-quinoline hybrids displayed significant
anti-malarial activity by ip route with ED50 values of 1.1,
1.4 and <0.8 mg/kg for hybrids 1, 2 – 3, respectively.
Despite a short half-life and moderate oral bioavailabil-
ity of the parent drug (as seen for hybrid 2), this class of
compounds was able to cure malaria in mice at very low
dosages, implying that the compounds are metabolized
to active metabolites. The next step will be to conduct a
comprehensive pharmacokinetic study, including metab-
olite identification.
In this study the optimum linker length for in vivo
anti-malarial activity was found to be a diaminoalkyl
chain consisting of two carbon atoms either methylated
or unmethylated as in hybrids 1 and 2. By introducing
another carbon atom in the linker chain, as in hybrid 3,
the survival rate was reduced from 100% to 66% at the
same dosages.
Additional files
Additional file 1: Raw data of treatment with hybrid 1 by ip route.
Parasitaemia of P. vinckei infected mice treated during four days
(D1 to D4) with hybrid 1 by intraperitoneal route at 0.8, 2.5, 7.5 and
15 mg/kg.
Additional file 2: Raw data of treatment with hybrid 1 by po route.
Parasitaemia of P. vinckei infected mice treated during four days
(D1 to D4) with hybrid 1 by oral route at 2.7, 8.3, 25 and 50 mg/kg.
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